<DOC>
	<DOC>NCT00549978</DOC>
	<brief_summary>to investigate the safety and pharmacokinetics, in healthy adult male subjects</brief_summary>
	<brief_title>Safety and Pharmacokinetics of Probucol and Cilostazol</brief_title>
	<detailed_description>Safety and Pharmacokinetics of Probucol and Cilostazol when co-administered in Health Subjects</detailed_description>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>Korean Gender: Male Age: Over 20 and Under 40years, at time of informed consent body weight: BMI over 19.0 and Under 25.0 Subjects who meet the following criteria at the time of the screening examination Subjects who have given their written informed consent prior to participation in the study Subjects who are reliable and willing to make themselves available for the duration of the study and follow the study protocol History or clinical evidence of significant respiratory, cardiovascular, renal, gastrointestinal, hepatic, endocrine, hematologic, neurologic, psychiatric, or other chronic disease, alcoholism, or drug abuse Present or previous significant drug allergy to any prescription or over the counter medication Blood collection exceeding 200ml within 4 weeks, 400ml within 12 weeks, or 1200ml within one year prior to scheduled study drug administration Body weight: under 50Kg</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Safety and Pharmacokinetics in healthy subjects</keyword>
</DOC>